These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 31743041)
21. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. Ben-Shlomo S; Zvibel I; Shnell M; Shlomai A; Chepurko E; Halpern Z; Barzilai N; Oren R; Fishman S J Hepatol; 2011 Jun; 54(6):1214-23. PubMed ID: 21145820 [TBL] [Abstract][Full Text] [Related]
22. Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice. Tudurí E; Beiroa D; Porteiro B; López M; Diéguez C; Nogueiras R Diabetes Obes Metab; 2015 Aug; 17(8):789-99. PubMed ID: 25962313 [TBL] [Abstract][Full Text] [Related]
23. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Lee YS; Jun HS Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094 [TBL] [Abstract][Full Text] [Related]
24. Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice. Nonogaki K; Kaji T Diabetes Metab; 2015 Nov; 41(5):425-8. PubMed ID: 26234524 [TBL] [Abstract][Full Text] [Related]
25. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Nauck M Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970 [TBL] [Abstract][Full Text] [Related]
26. Portal milieu and the interplay of multiple antidiabetic effects after gastric bypass surgery. Pal A; Rhoads DB; Tavakkoli A Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G668-G678. PubMed ID: 30896970 [TBL] [Abstract][Full Text] [Related]
27. Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes. Dalle S; Burcelin R; Gourdy P Cell Signal; 2013 Feb; 25(2):570-9. PubMed ID: 23159576 [TBL] [Abstract][Full Text] [Related]
29. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. D'Alessio D; Lu W; Sun W; Zheng S; Yang Q; Seeley R; Woods SC; Tso P Am J Physiol Regul Integr Comp Physiol; 2007 Dec; 293(6):R2163-9. PubMed ID: 17898126 [TBL] [Abstract][Full Text] [Related]
30. The relationship between anagliptin concentration showing over 80% inhibition of plasma dipeptidyl peptidase-4 activity and its protective effect against glucagon-like peptide-1 degradation. Furuta S; Goto M; Tamura M; Yamashita S; Nakaya K; Furuta Y Drug Res (Stuttg); 2014 Mar; 64(3):130-5. PubMed ID: 23965798 [TBL] [Abstract][Full Text] [Related]
31. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Flock G; Baggio LL; Longuet C; Drucker DJ Diabetes; 2007 Dec; 56(12):3006-13. PubMed ID: 17717280 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366 [TBL] [Abstract][Full Text] [Related]
34. Intraportal infusion of ghrelin could inhibit glucose-stimulated GLP-1 secretion by enteric neural net in Wistar rat. Zhang X; Li W; Li P; Chang M; Huang X; Li Q; Cui C Biomed Res Int; 2014; 2014():923564. PubMed ID: 25247193 [TBL] [Abstract][Full Text] [Related]
35. Is GLP-1 a hormone: Whether and When? D'Alessio D J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):50-5. PubMed ID: 27186356 [TBL] [Abstract][Full Text] [Related]
36. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Burcelin R; Da Costa A; Drucker D; Thorens B Diabetes; 2001 Aug; 50(8):1720-8. PubMed ID: 11473030 [TBL] [Abstract][Full Text] [Related]
37. Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes. Grespan E; Giorgino T; Natali A; Ferrannini E; Mari A Metabolism; 2021 Jan; 114():154415. PubMed ID: 33137379 [TBL] [Abstract][Full Text] [Related]
38. Patients With Long-QT Syndrome Caused by Impaired Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848 [TBL] [Abstract][Full Text] [Related]